Τίτλος:
Immunohisto(cyto)chemistry: an old time classic tool driving modern
oncological therapies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
In the era of precision medicine immunohistochemistry (IHC) and
immunocytochemistry (ICC) share some of the highlights in personalized
treatment. Survival data obtained from clinical trials shape the
cut-offs and IHC scoring that serve as recommendations for patient
selection both for targeted and conventional therapies. Assessment of
Estrogen and Progesterone Receptors along with HER2 status has been
among the first approved immunostaining assays revolutionizing breast
cancer treatment. Similarly, ALK positivity predicts the efficacy of ALK
inhibitors in patients with non-small cell lung cancer (NSCLC). In
recent years, Programmed Death Ligand 1 (PD-L1) IHC assays have been
approved as companion or complimentary diagnostic tools predicting the
response to checkpoint inhibitors. Anti-PD-L1 and anti-PD-1 monoclonal
antibodies have inaugurated a new period in the treatment of advanced
cancers, but the path to approval of these biomarkers is filled with
immunohistochemical challenges. The latter brings to the fore the
significance of molecular pathology as a hub between basic and clinical
research. Besides, novel markers are translated into routine practice,
suggesting that we are at the beginning of a new exciting period.
Unraveling the molecular mechanisms involved in cellular homeostasis
unfolds biomarkers with greater specificity and sensitivity. The
introduction of GL13 (SenTraGor (R)) for the detection of senescent
cells in archival material, the implementation of key players of stress
response pathways and the development of compounds detecting common
mutant P53 isoforms in dictating oncological treatments are paradigms
for precision oncology.
Συγγραφείς:
Cooks, Tomer
Theodorou, Sofia D. P.
Paparouna, Eleni
Rizou,
Sophia V.
Myrianthopoulos, Vassilios
Gorgoulis, Vassilis G. and
Pateras, Ioannis S.
Περιοδικό:
HISTOLOGY AND HISTOPATHOLOGY
Λέξεις-κλειδιά:
Biomarkers; Immunohistochemistry; Immunocytochemistry; Oncology; Therapy
